Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.6101
+0.0189 (3.20%)
Apr 16, 2026, 11:41 AM EDT - Market open
Cytosorbents Stock Forecast
Stock Price Forecast
The 2 analysts that cover Cytosorbents stock have a consensus rating of "Buy" and an average price target of $5.38, which forecasts a 781.82% increase in the stock price over the next year. The lowest target is $0.75 and the highest is $10.
Price Target: $5.38 (+781.82%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytosorbents stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,539.08% | Mar 26, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,539.08% | Jan 12, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,539.08% | Dec 16, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,539.08% | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $0.75 | Hold | Maintains | $1 → $0.75 | +22.93% | Nov 14, 2025 |
Financial Forecast
Revenue This Year
40.90M
from 37.06M
Increased by 10.34%
Revenue Next Year
50.06M
from 40.90M
Increased by 22.41%
EPS This Year
-0.17
from -0.13
EPS Next Year
-0.06
from -0.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 42.8M | 53.6M | |||
| Avg | 40.9M | 50.1M | |||
| Low | 38.3M | 46.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 15.6% | 31.0% | |||
| Avg | 10.3% | 22.4% | |||
| Low | 3.4% | 12.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.16 | -0.05 | |
| Avg | -0.17 | -0.06 | |
| Low | -0.19 | -0.07 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.